NASDAQ:DRRX - DURECT Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$1.30 -0.01 (-0.76 %)
(As of 08/15/2018 04:00 PM ET)
Previous Close$1.31
Today's Range$1.27 - $1.34
52-Week Range$0.75 - $2.55
Volume332,974 shs
Average Volume831,211 shs
Market Capitalization$226.80 million
P/E Ratio-43.33
Dividend YieldN/A
Beta1.12
DURECT logoDURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including REMOXY ER, an investigational extended release pain relief drug based on ORADUR technology; and POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Sandoz AG; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.

Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DRRX
CUSIPN/A
Phone408-777-1417

Debt

Debt-to-Equity Ratio0.44
Current Ratio3.60
Quick Ratio3.36

Price-To-Earnings

Trailing P/E Ratio-43.33
Forward P/E Ratio-6.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$49.17 million
Price / Sales4.28
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book9.29

Profitability

EPS (Most Recent Fiscal Year)($0.03)
Net Income$-3,690,000.00
Net Margins-2.04%
Return on Equity-4.27%
Return on Assets-1.69%

Miscellaneous

Employees93
Outstanding Shares162,000,000
Market Cap$226.80 million

DURECT (NASDAQ:DRRX) Frequently Asked Questions

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings data on Wednesday, August, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. The specialty pharmaceutical company had revenue of $3.41 million for the quarter, compared to the consensus estimate of $3.83 million. DURECT had a negative return on equity of 4.27% and a negative net margin of 2.04%. View DURECT's Earnings History.

When is DURECT's next earnings date?

DURECT is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for DURECT.

What price target have analysts set for DRRX?

3 Wall Street analysts have issued 1-year price objectives for DURECT's stock. Their forecasts range from $2.00 to $3.00. On average, they expect DURECT's share price to reach $2.50 in the next year. This suggests a possible upside of 92.3% from the stock's current price. View Analyst Price Targets for DURECT.

What is the consensus analysts' recommendation for DURECT?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DURECT.

Who are some of DURECT's key competitors?

Who are DURECT's key executives?

DURECT's management team includes the folowing people:
  • Dr. Felix Theeuwes, Co-Founder, Chairman & Distinguished Scientist (Age 80)
  • Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 61)
  • Mr. Matthew J. Hogan, CFO & Sec. (Age 58)
  • Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 61)
  • Mr. Michael H. Arenberg J.D., M.B.A., Sr. VP of Corp. & Bus. Devel.

Has DURECT been receiving favorable news coverage?

Press coverage about DRRX stock has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. DURECT earned a news and rumor sentiment score of 0.14 on Accern's scale. They also gave news articles about the specialty pharmaceutical company an impact score of 46.45 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for DURECT.

Who are DURECT's major shareholders?

DURECT's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.14%), Renaissance Technologies LLC (2.02%), Gagnon Securities LLC (0.92%), Tocqueville Asset Management L.P. (0.72%), Acadian Asset Management LLC (0.56%) and Smith Asset Management Group LP (0.44%). View Institutional Ownership Trends for DURECT.

Which institutional investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Algert Global LLC, Tocqueville Asset Management L.P. and Asymmetry Capital Management L.P.. View Insider Buying and Selling for DURECT.

Which institutional investors are buying DURECT stock?

DRRX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Smith Asset Management Group LP, Acadian Asset Management LLC, Gagnon Securities LLC, Alambic Investment Management L.P., United Services Automobile Association, Alps Advisors Inc. and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for DURECT.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $1.30.

How big of a company is DURECT?

DURECT has a market capitalization of $226.80 million and generates $49.17 million in revenue each year. The specialty pharmaceutical company earns $-3,690,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis. DURECT employs 93 workers across the globe.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.


MarketBeat Community Rating for DURECT (NASDAQ DRRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  309
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/15/2018 by MarketBeat.com Staff

Featured Article: Trading Strategy

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.